StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $0.97 | $0.96 | -0.72% | 0.1M |
| 05-14 | $0.96 | $1.04 | +8.00% | 0.6M |
| 05-15 | $1.06 | $1.01 | -4.72% | 0.2M |
| 05-18 | $1.03 | $0.94 | -8.73% | 0.3M |
| 05-19 | $0.94 | $0.88 | -6.84% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for SNTI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Fundamentals not available for SNTI.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $16.00K | $22.00K | $0.00 | $0.00 |
Operating Income | $-4.62M | $-68.78M | $-16.40M | $-61.04M |
Net Income | $-4.22M | $-61.44M | $-14.11M | $-52.79M |
EPS (Diluted) | $-0.14 | $-2.73 | $-1.41 | $-12.03 |
Total Assets | $38.24M | $51.22M | $82.78M | $97.84M |
Total Liabilities | $35.68M | $45.63M | $44.92M | $47.09M |
Cash & Equivalents | $8.94M | $16.42M | $33.80M | $48.28M |
Free Cash Flow OCF − CapEx | Not available | $-43.64M | $-14.05M | $-41.42M |
Shares Outstanding | 31.14M | 30.88M | 26.00M | 4.83M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.